SCHEMBL31015283

SCHEMBL31015283

CCOC(=O)c1cnc(-c2cncc(N3CCCC3)n2)o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
KDM4E B2RXH2 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
NLRP3 Q96P20 1/20 0.40
PIK3CA P42336 1/20 0.38
PDE4B Q07343 1/20 0.38
CDC7 O00311 2/20 0.38
PIM2 Q9P1W9 2/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
ADORA3 P0DMS8 2/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
DBF4 Q9UBU7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31015138 0.84 PIM2 (0.40) PIM2POLBFFAR4DYRK1A
SCHEMBL31014522 0.83 PIM2 (0.43) PIM2FFAR4DYRK1A
SCHEMBL31015614 0.82 AOC3 (0.38) KDM4EPIM2FFAR4DYRK1A
SCHEMBL25098746 0.80 CDC7 (0.40) NPC1RAB9AKDM4ENLRP3CDC7
SCHEMBL17869189 0.75 KMT2A (0.46) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL31014738 0.73 PIM2 (0.40) PIM2FFAR4DYRK1A
SCHEMBL15465637 0.70 HDAC4 (0.40) NPC1RAB9AKDM4ENLRP3CDC7
SCHEMBL22619844 0.69 LMNA (0.50) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL16923870 0.69 MAPT (0.52) KMT2AMEN1POLBMAPTL3MBTL1
SCHEMBL31589706 0.69 ALDH1A1 (0.48) KMT2AMEN1NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KMT2A 208/4885MEN1 1196/4885NPC1 1608/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 KMT2A 208/4885MEN1 1196/4885NPC1 1608/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 KMT2A 208/4885MEN1 1196/4885NPC1 1608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.